-
NewAmsterdam Pharma Company NV NasdaqGM:NAMS NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Location: Gooimeer 2-35, Naarden, 1411 DC, Netherlands | Website: https://www.newamsterdampharma.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
1.312B
Cash
808.5M
Avg Qtr Burn
-35.11M
Short % of Float
9.95%
Insider Ownership
0.35%
Institutional Own.
-
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Obicetrapib Details Heterozygous familial hypercholesterolemia, Atherosclerotic cardiovascular disease | Phase 3 Data readout | |
Obicetrapib + ezetimibe Details Dyslipidemia, Hypercholesterolemia | Phase 3 Data readout | |
Obicetrapib Details Alzheimer's disease | Phase 2a Update |